X4 Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

X4 Pharmaceuticals

21/03/2023 13:31

* X4 Pharmaceuticals Inc  XFOR.OQ  reported a quarterly
adjusted
loss of 29 cents​​ per share for the quarter ended in December.
The mean expectation of eight analysts for the quarter was for a
loss of 24 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * X4 Pharmaceuticals Inc's reported EPS for the quarter was
a loss
of 29 cents​.
    * The mean earnings estimate of analysts had risen by
about 4.6%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates 
    * X4 Pharmaceuticals Inc shares had fallen by 10.7% this
quarter.
    * The company reported a quarterly loss of $29.1 million.
    * Wall Street's median 12-month price target for X4
Pharmaceuticals Inc is $4.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 21 at 01:30 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.24          -0.29          Missed
 Sep. 30 2022      -0.30          -0.26          Beat
 Jun. 30 2022      -0.64          -0.60          Beat
 Mar. 31 2022      -0.61          -0.72          Missed